Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Blood proteins or globulins – e.g. – proteoglycans – platelet...
Reexamination Certificate
2007-10-10
2011-11-29
Saoud, Christine J (Department: 1647)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Blood proteins or globulins, e.g., proteoglycans, platelet...
C530S387100, C530S388220, C530S388800, C424S130100, C424S138100, C424S141100, C424S143100, C435S326000, C435S330000
Reexamination Certificate
active
08067550
ABSTRACT:
The present invention relates to the production of anti non functional P2X7 receptor monoclonal antibodies from hybridoma cell lines.
REFERENCES:
patent: 6133434 (2000-10-01), Buell et al.
patent: 6303338 (2001-10-01), Ni et al.
patent: 6306393 (2001-10-01), Goldenberg
patent: 6329503 (2001-12-01), Afar et al.
patent: 6709832 (2004-03-01), Von Knebel Doeberitz
patent: 7183064 (2007-02-01), Slater et al.
patent: 7326415 (2008-02-01), Barden et al.
patent: 7531171 (2009-05-01), Barden et al.
patent: 7767789 (2010-08-01), Gorodeski et al.
patent: 7888473 (2011-02-01), Barden et al.
patent: 2007/0020706 (2007-01-01), Gorodeski et al.
patent: 2007/0248963 (2007-10-01), Slater et al.
patent: 2008/0131438 (2008-06-01), Barden et al.
patent: 2008/0227122 (2008-09-01), Barden et al.
patent: 2011/0092674 (2011-04-01), Barden et al.
patent: 64184/98 (1998-10-01), None
patent: 2284859 (2007-01-01), None
patent: 1006186 (1998-10-01), None
patent: WO 92/16558 (1992-10-01), None
patent: WO 95/33048 (1995-12-01), None
patent: WO 97/06256 (1997-02-01), None
patent: WO 97/41222 (1997-11-01), None
patent: WO 98/42835 (1998-10-01), None
patent: WO 00/050458 (2000-08-01), None
patent: WO 01/06259 (2001-01-01), None
patent: WO 01/30964 (2001-05-01), None
patent: WO 02/57306 (2002-07-01), None
patent: WO 02/057306 (2002-07-01), None
patent: WO 03/002762 (2003-03-01), None
patent: WO 2004/092384 (2004-10-01), None
patent: WO 08/043145 (2008-04-01), None
patent: WO 08/043146 (2008-04-01), None
Barden J. A. et al. “Specific Detection of Non-Functional Human P2X7Receptors in HEK293 Cells and B-Lymphocytes” FEBS Letters (2003) 538: 159-162.
Gu B. J. ete al. “An Arg307to Gln Polymorphism Within the ATP-Binding Site Causes Loss of Function of Human P2X7Receptors” Journal of Biological Chemistry (2004) 279 (30) 31287-3195.
Wiley J. S. et al. “An lle-568 to Asn Polymorphism Prevents Normal Trafficking and Function of the Human P2X7Receptor” Journal of Biological Chemistry (2003) 278 (19): 17108-17113.
U.S. Appl. No. 12/445,258, filed Apr. 10, 2009, Gidley-Baird et al.
Bird et al., “Single-Chain Antigen-Binding Proteins”,Science, 242(4877):423-426, (1988).
Buell et al., “P2X Receptors: An Emerging Channel Family”,Eur J Neurosci, 8:2221-2228, (1996).
Cheewatrakoolpong et al., “Identification and characterization of splice variants of the human P2X7ATP channel”,Biochem and Biophysical Res Comm, 332:17-27, (2005).
Dangl et al., “Rapid Isolation of Cloned Isotype Switch Variants Using Fluorescence Activated Cell Sorting”, Cytometry 2(6): 395-401, (1982).
Di Virgilio et al., “Responses of Mouse Lymphocytes to Extracellular Adenosine 5'-Triphosphate (ATP)”,J Immunology, 143(6):1955-1960, (1989).
Dubyak et al, “Signal transduction via P2-purinergic receptors for extracellular ATP and other nucleotides”,Am J Physiol, 265(Cell Physiol. 34):C577-C606, (1993).
Feng et al., “A Truncated P2X7Receptor Variant (P2X7-j) Endogenously Expressed in Cervical Cancer Cells Antagonizes the Full-length P2X7Receptor Through Hetero-oligomerization”,J Biol Chem, 281(25):17228-17237, (2006).
Ferrari et al., “P2Z purinoreceptor ligation induces activation of caspases with distinct roles in apoptotic and necrotic alterations of cell death”,FEBS Letters, 447:71-75, (1999).
Galfre et al., “Antibodies to major histocompatibility antigens produced by hybrid cell lines”,Nature, 266:550-552, (1977).
Galfre et al., “Rat x rat hybrid myelomas and a monoclonal anti-Fd portion of mouse IgG”,Nature, 277:131-133, (1979).
Gefter et al., “A Simple Method for Polyethylene Glycol-Promoted Hybridization of Mouse Myeloma Cells”,Somatic Cell Genetics, 3(2):231-236, (1977).
Georgiou et al., “Human Epidermal and Monocyte-Derived Langerhans Cells Express Functional P2X7Receptors”,J Invest Dermatol, 125:482-490. (2005).
Holliger et al., “‘Diabodies’.: Small bivalent and bispecific antibody fragments”,Proc Natl Acad Sci, 90:6444-6448, (1993).
Huston et al., “Protein engineering of antibody binding sites: Recovery of specific activity in an anti-digoxin single-chain Fv analogue produced inEscherichia coli”,Proc Natl Acad Sci, 85:5879-5883, (1988).
Kim et al., “Differential Assembly of Rat Purinergic P2X7Receptor in Immune Cells of the Brain and Periphery”,J Biol Chem, 276(26):23262-23267, (2001).
La Sala et al., “Alerting and tuning the immune response by extracellular nucleotides”,J Leukocyte Bio, 73:339-343, (2003).
Poljak, “Production and structure of diabodies”,Structure, 2:1121-1123, (1994).
Ralevic et al., “Receptors for Purines and Pyrimidines”,Pharm Rev, 50(3):413-492, (1998).
Romagnoli et al., “Recent progress in the discovery of antagonists acting at P2X7receptor”,Expert Opin Ther Patents, 15(3):271-287, (2005).
Slater et al., “Early prostate cancer detected using expression of non-functional cytolytic P2X7receptors”,Histopathology, 44:206-215, (2004).
Slater et al., “Expression of the apoptotic calcium channel P2X7in the glandular epithelium is a marker for early prostate cancer and correlates with increasing PSA levels”,J Mol Hist, 36:159-165, (2005).
Spieker-Polet et al., “Rabbit monoclonal antibodies: Generating a fusion partner to produce rabbit-rabbit hybridomas”,Proc Natl Acad Sci, 92:9348-9352, (1995).
Surprenant et al., “The Cytolytic P2zReceptor for Extracellular ATP Identified as a P2xReceptor (P2X7)”, Science, 272:735-738, (1996).
Torres et al., “Hetero-oligomeric Assembly of P2X Receptor Subunits”,J Biol Chem, 274(10):6653-6659, (1999).
Virginio et al., “Kinetics of cell lysis, dye uptake and permeability changes in cells expressing the rat P2X7receptor”,J Physiol, 519(2):335-346, (1999).
Wang et al., “P2X7receptor-mediated apoptosis of human cervical epithelial cells”,Am J Physiol Cell Physiol, 287:C1349-C1358, (2004).
Ward et al., “Binding activities of a repertoire of single immunoglobulin variable domains secreted fromEscherichia coli”,Nature, 341:544-546, (1989).
U.S. Appl. No. 12/878,865, filed May 12, 2011, Slater et al.
U.S. Appl. No. 12/975,341, filed Apr. 21, 2011, Barden et al.
U.S. Appl. No. 60/686,770, filed Jun. 2, 12005, Gorodeski et al.
U.S. Appl. No. 60/778,993, filed Mar. 3, 2006, Gorodeski et al.
Buell et al.,“Blockade of Human P2X7 Receptor Function With a Monoclonal Antibody,”Blood, 92:3521-3528, (1998).
Burnstock et al., “P2 Purinergic Receptors: Modulation of Cell Function and Therapeutic Potential,”J Pharm Exp Therap, 295:862-869, (2000).
Chessell et al., “Dynamics of P2X7 receptor pore dilation: pharmacological and functional consequences,”Drug Dev Res, 53(2-3):60-65, (2001).
Di Virgiolio et al., “Purinergic P2X7 receptor: a pivotal role in inflammation and immunomodulation,”Drug Dev Res, 45:207-213, (1998).
European Search Report of Apr. 1, 1997 for application EP96120926 (published as EP0781546).
European Search Report of Sep. 18, 2008 for application EP08156593 (published as EP1961767).
Feng et al., “ATP Stimulates GRK-3 phosphorylation and 3-arrestin-2-dependent internalization of P2X7 receptor,”Am J Physiol Cell Physiol, 288:C1342-C1356, (2005).
Feng et al., “Endogenously Expressed Truncated P2X7 Receptor Lacking the C-Terminus is Preferentially Upregulated in Epithelial Cancer Cells and Fails to Mediate LigandInduced Pore Formation and Apoptosis, ”Nucleosides, Nucleotides and Nucleic Acids, 25:1271-1276, (2006).
Ferrari et al., “ATP-mediated cytoxicity in microglial cells,”Neuropharmacology, 36(9):1295-1301, (1997).
GenBank: Accession No. Y09561, versions Y09561.1, “H. sapiens mRNA for P2X7 receptor”. [Retrieved from the Internet May 24, 2011: <URL: http://www.ncbi.nlm
Barden Julian Alexander
Gidley-Baird Angus
Alston and Bird LLP
Biosceptre International Limited
Lockard Jon M
Saoud Christine J
LandOfFree
Hybridomas producing antibodies against non functional P2X7... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Hybridomas producing antibodies against non functional P2X7..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Hybridomas producing antibodies against non functional P2X7... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4292569